https://scholars.lib.ntu.edu.tw/handle/123456789/627195
Title: | Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma | Authors: | Rimassa, Lorenza Kelley, Robin Kate Meyer, Tim Ryoo, Baek-Yeol Merle, Philippe Park, Joong-Won Blanc, Jean-Frederic Lim, Ho Yeong Tran, Albert Chan, Yi-Wah McAdam, Paul Wang, Evelyn ANN-LII CHENG El-Khoueiry, Anthony B Abou-Alfa, Ghassan K |
Keywords: | Cabozantinib; Hepatocellular carcinoma; Plasma biomarkers; Prognostic factors | Issue Date: | Jan-2022 | Publisher: | KARGER | Journal Volume: | 11 | Journal Issue: | 1 | Source: | Liver cancer | Abstract: | Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In this exploratory analysis, outcomes were evaluated according to plasma biomarker levels. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627195 | ISSN: | 2235-1795 | DOI: | 10.1159/000519867 |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.